section name header

Pronunciation

FEN-el-zeen

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: monamine oxidase inhibitors

Indications

REMS


Action

  • Inhibits the enzyme monoamine oxidase, resulting in an accumulation of various neurotransmitters (dopamine, epinephrine, norepinephrine, and serotonin) in the body.
Therapeutic effects:
  • Improved mood in depressed patients.

Pharmacokinetics

Absorption: Well absorbed from the GI tract.

Distribution: Crosses the placenta and probably enters breast milk.

Metabolism/Excretion: Metabolized by the liver; excreted in urine as metabolites and unchanged drug.

Half-Life: 12 hr.

Time/Action Profile

(antidepressant effect)

ROUTEONSETPEAKDURATION
PO2–4 wk3–6 wk2 wk





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, orthostatic hypotension, HYPERTENSIVE CRISIS

Derm: pruritis, rashes

EENT: blurred vision, glaucoma, nystagmus

Endo: weight gain

F and E: hypernatremia

GI: constipation, dry mouth, abdominal pain, liver function test elevation, nausea, vomiting

GU: sexual dysfunction, urinary retention

Neuro: dizziness, drowsiness, fatigue, headache, hyperreflexia, insomnia, tremor, twitching, weakness, euphoria, paresthesia, restlessness, SEIZURES

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Nardil